BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $2 | $2 | $2 | $1 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $2 | $2 | $1 | $1 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 17% | 7.7% | 7.7% | -4.5% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | $1 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS | 2.25 | 0.89 | 0.76 | -0.35 |
| % Growth | 152.8% | 17.1% | 317.1% | – |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |